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Abstract
Background: Phenylketonuria (PKU) is a rare genetic disorder caused by a defect in the metabolism of phenylalanine
(PHE) resulting in elevated blood and brain PHE levels, and leading to cognitive, emotional, and psychosocial problems.
The phenylketonuria – quality of life (PKU-QOL) questionnaire was the first self-administered disease-specific instrument
developed to assess the impact of PKU and its treatment on the health-related quality of life (HRQL) of patients and
their caregivers. Available in four versions (child, adolescent, adult and parent), the PKU-QOL was simultaneously
developed and validated in seven countries [i.e., France, Germany, Italy, The Netherlands, Spain, Turkey and the United
Kingdom (UK)]. The objectives of our study were to develop and linguistically validate the PKU-QOL questionnaire for
use in the United States (US).
Methods: The UK versions served as a basis for the development of the US English PKU-QOL questionnaire.
The linguistic validation process consisted of 4 steps: 1) adaptation of the UK versions into US English by a
translator native of US English and living in the US; 2) a clinician review; 3) cognitive interviews with patients
and caregivers to test the appropriateness, understandability and clarity of the US translations; and 4) two
proof-readings.
Results: The adaptation from UK to US English revealed the usual syntactic and idiomatic differences between the
two languages, such as differences in: 1) Spelling, e.g., “dietician” (UK) vs. “dietitian” (US), or “mum” (UK) vs. “mom” (US);
2) Syntax or punctuation; and 3) Words/expressions use, e.g., “holidays” (UK) vs. “vacation” (US), or “biscuits” (UK) vs.
“crackers” (US). The major issue was cultural, and consisted of using a different terminology to describe PKU treatment
throughout the questionnaires. The clinician, with the patients and the caregivers, during the interviews suggested
to replace “supplement and amino-acid mixture” or “supplements” with “medical formula.” This wording was later
changed to “medical food” to be consistent with the terminology used in current US published guidelines.
Conclusions: The translation of the UK English PKU-QOL questionnaire into US English did not raise critical
semantic and cultural issues. The PKU-QOL will be valuable for US healthcare providers in individualizing
treatment and managing patients with PKU.
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Background
Phenylketonuria (PKU), or phenylalanine hydroxylase
deficiency (PAHD), is a rare autosomal recessive disease,
induced by the deficiency of the hepatic enzyme, phenyl-
alanine hydroxylase (PAH) that converts the essential
amino acid phenylalanine (PHE) into tyrosine (TYR) [1].
This defect results in increased blood concentrations of
PHE and toxic accumulation in the brain, leading to
cognitive deficiencies, emotional disturbance and psy-
chosocial disabilities [1, 2]. Current treatment for PKU
includes a life-long diet highly restrictive in PHE that
excludes high protein foods, and is supported nutrition-
ally with medical foods [3] with the goal of maintaining
blood PHE in the range of 120–360 μmol/l [3]. Medical
foods for PKU provide the amino acids required for
normal growth and development, without PHE or with
negligible amounts of PHE, and include conditionally
essential TYR and varying quantities of carbohydrate, fat,
vitamins, and minerals [4, 5]. Pharmacological treatment
with sapropterin dihydrochloride (KUVAN® BioMarin
Pharmaceutical Inc., Novato, CA) is to date the only Food
and Drug Administration (FDA) approved medication in-
dicated for the treatment of PKU in conjunction with a
PHE-restricted diet in individuals with tetrahydrobiopterin
(BH4)-responsive PKU [3, 6]. Although the mechanism of
action underlying the BH4 therapeutic effect is not entirely
understood, it is thought that the primary mechanism-of-
action for BH4 treatment in PKU is the activation of
residual PAH enzyme resulting in increased PHE oxida-
tion to TYR [7, 8]. Research suggests that approximately
50% of PKU patients in the US could exhibit a beneficial
response to BH4 [9].
The PHE-restricted diet can be burdensome to indi-
viduals with PKU and their families, leading to a risk of
non-adherence with treatment, especially in adolescents
and young adults [10–13]. Obstacles to treatment adher-
ence include time constraints and stress associated with
food preparation and record keeping, as well as restric-
tions imposed on social life. In addition, medical foods
and specialty low protein foods may be poorly accepted
and can impose a financial burden [11]. Diminishing ad-
herence with age is a global issue. In a study surveying
ten European centers, Ahring et al. [14] showed blood
PHE control and the percentages of blood PHE concen-
trations within each center’s local and national target
ranges diminished for patients above 16 years of age.
Psychological and neurocognitive problems may be
observed in individuals with PKU [15]. In a systematic
literature review [16], Enns et al. reported that overall
intellectual functioning and specific neuropsychological
abilities may be suboptimal in patients treated with diet
only and having either high or fluctuating blood PHE
concentrations. They described executive dysfunction
in working memory, conceptual reasoning, mental
flexibility and organizational strategy. Attentional prob-
lems leading to negative impacts on academic progress, as
well as on self-esteem and emotional development, were
noted. Regarding the evaluation of quality of life (QOL),
Enns et al. described contrasting results. Out of six studies
reviewed, two presented optimal outcomes, i.e., QOL
comparable to normal controls [17, 18] and four reported
suboptimal results [19–22]. However, more recent studies
(published after Enns et al.’s review) suggest that the QOL
of patients with PKU is often comparable to that of the
general population [23–27]. Common to these studies is
the use of generic measures to assess QOL, i.e. question-
naires intended for use irrespective of the underlying dis-
ease. This suggests that the observation of normal QOL
outcomes might be the result of the lack of specificity of
these generic questionnaires, not specifically designed to
address the impact of PKU and its treatment on patients’
lives, therefore, failing to assess more subtle problems
that may be experienced by individuals with PKU. For
instance, in their evaluation of BH4 on quality of life,
Ziesch et al. [23] used the KINDL (Kinder Lebensqua-
lität), a generic measure of QOL for children (origin-
ally developed in German). They noticed that QOL
results conflicted with personal reports from children
and parents, felt to be related to the use of the
KINDL which did not capture aspects that mattered
to the patients. As a result, they called for the devel-
opment of a specific disease-related PKU QOL instru-
ment. Such an instrument should be able to detect
decrements in specific domains of the life of patients
with PKU as well as potential improvements in these
domains due to therapeutic interventions.
The phenylketonuria – quality of life (PKU-QOL)
questionnaire was developed to address these issues
[28]. This is the first self-administered instrument devel-
oped for patients with PKU and their caregivers which
assesses PKU symptoms, PKU in general (i.e., physical,
emotional, social and overall impacts of PKU), and the
impact of treatment. The PKU-QOL exists in four ver-
sions, three are age-specific [Child (9–11 years old)
PKU-QOL (40 items), Adolescent (12–17 years old)
PKU-QOL (58 items), Adult PKU-QOL (65 items)], and
one version enables the evaluation of the QOL of chil-
dren by their caregivers as well as an assessment of the
parents’ QOL [Parent PKU-QOL (54 items)]. The four
versions share a similar structure, but reflect the specific
realities of each population. The PKU-QOL was simul-
taneously developed and validated in seven countries
(i.e., France, Germany, Italy, The Netherlands, Spain,
Turkey and the UK).
The objectives of our study were to adapt and linguis-
tically validate the PKU-QOL for use in the United
States by healthcare providers to evaluate the QOL of
patients with PKU.
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Methods
Linguistic validation process
The linguistic validation process used to develop the US
version of the PKU-QOL was in compliance with the
recommendations of the International Society for Phar-
macoeconomics and Outcomes Research [29, 30]. The
UK questionnaire served as a basis for the development
of the US English PKU-QOL.
The process, conducted by a coordinating center (i.e.,
Mapi Language Services), consisted of 4 steps. The first
step was adapting the UK English version of the PKU-
QOL questionnaire to US English. The source UK
English version of the PKU-QOL was assessed for its
suitability in the linguistic and cultural context of the
US, and its wording was adapted when needed. The
adaptation was performed by a translator native of US
English and living in the US. It is important this step be
performed in the target country (i.e., US), to make sure
the version is adapted to the contemporary context of
the country in which it will be used. Discussion with the
coordinating center led to the development of a first
target US version. A report summarizing the issues
encountered and solutions retained was developed. A sec-
ond step was a clinician review to obtain input from med-
ical experts on specific terminology used. Issues and
solutions were discussed with the coordinating center and
the in-country translator. The third step consisted of in-
depth cognitive individual interviews with patients and
caregivers. The objective was to investigate the appropri-
ateness, understandability and clarity of the US PKU-QOL
questionnaire. Participants were asked to comment on
their understanding of each part of the questionnaire (i.e.,
instructions, questions and response categories) and sug-
gest alternative formulations where wording was thought
to be problematic. Difficulties were scrutinized and solu-
tions were proposed during discussions between the
coordinating center and the in-country-consultant. Finally,
two proof-readings were conducted by two translators
working independently (i.e., the in-country consultant and
one translator new to the study).
Participants
Patients with a formal diagnosis of PKU were re-
cruited by medical experts from sites in the US who
agreed to participate in this study. Medical experts
were asked to recruit patients of specified ages ac-
cording to the questionnaire being evaluated. Patients
and their caregivers were included if they agreed to
participate in the interviews. Patients were not re-
cruited based on their phenotype. Participants in the
interviews had to be native English-speaking residents
of the US. Participants were not included if they were
not able or willing to provide informed consent and
were not native US English speakers.
Analysis
The linguistic validation report was reviewed to identify
difficulties and problematic issues, as well as the solu-
tions proposed to overcome them. The types of difficul-
ties were categorized as Cultural (C), Idiomatic (I),
Semantic/conceptual (S) or Syntactic (Sy) (Table 1).
Results
Participants
Interviews were conducted with 15 patients and 5 care-
givers of patients with PKU (Table 2). The US versions
of the PKU-QOL were administered as follows: Child
PKU-QOL to five children; Adolescent PKU-QOL to five
adolescents; Adult PKU-QOL to five adults; and Parent
PKU-QOL to five parents of the children/adolescents
already recruited to test the children and adolescent
versions.
Table 1 Categorization of translation difficulties
Category Definition
Cultural (C) A word or formulation in the original is culturally loaded in the target context due to societal or religious customs
(e.g., eating habits in Asian countries). The usage of certain words or phrases based on the culture of a given society
may be improper in the target language.
For instance,, starchy foods (e.g., potato, bread, etc.), starchy foods (e.g.,. rice, pasta, chapatti, etc.).
Semantic (S) Semantics concerns meanings, which are both denotative, i.e. the literal word (lexis), and connotative, namely the set
of cultural and/or subjective associations implied by a word in addition to its literal explicit meaning. This category
includes lexical differences.
For instance, meet your responsibilities, meet your duties, meet your obligations.
Idiomatic/pragmatics (I) The practicalities of how a language is used in its everyday context are different between the source and target
language. For example, one language may have more social registers than another (there are a number of different
forms of addressing a person in Japanese, whereas English may only have one) and the idiosyncrasies of one
language (repetitions, focus on particular words, use of idiomatic expressions, etc.) may not be found in another.
For instance, I feel downhearted and blue, I feel down and sad.
Syntactic/grammar (Sy) Syntactic difficulties correspond to specific aspects related to sentence structure, grammar, punctuation. The structure
and grammar of the source and target language may diverge. For example, there is no grammatical form for the past
tense in Tagalog.
For instance, How flexible have you been finding…? How flexible have you found…?
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The general impression reported was favorable. The
questionnaire on the whole was reported to be clearly
worded and easy to understand. The instructions, as well
as the response choices, were found to be straightfor-
ward and free from ambiguity. For each item, respon-
dents had no difficulty in choosing their answer.
Adaptation issues
The adaptation from UK to US English revealed the
usual semantic (S), syntactic (Sy) and idiomatic (I) differ-
ences between the two languages, such as differences in:
1) Spelling (S): i.e., “dietician” (UK) vs. “dietitian” (US);
“mum” (UK) vs. “mom” (US).
2) Syntax or punctuation (Sy): i.e., “I was so angry I
wanted to hit something or someone” (UK) vs. “I
was so angry that I wanted to hit something or
someone” (US); ‘X’ (UK) vs. “X” (US).
3) Words/expressions use (S/I): i.e., “holidays” (UK) vs.
“vacation” (US); “please tick the box” (UK) vs.
“please check the box” (US); “Following are…” (UK)
vs. “Below there are…” (US); “biscuits” (UK) vs.
“crackers” (US); “filling in” (UK) vs. “filling out”
(US).
At a cultural level, date format i.e., “day/month/year”
(UK) was replaced by “month/day/year” (US). The ter-
minology to describe PKU treatment throughout the
questionnaires was changed in order to be fully under-
stood by the patients and caregivers. During the inter-
views, the clinicians, patients and caregivers, suggested
simplification of the terminology by replacing “supple-
ment and amino-acid mixture” or “supplements” with a
single expression, i.e., “medical formula.” This wording
was later changed to “medical food” to be consistent
with the terminology used in current US published
guidelines [3, 5].
In contrast, words involving feelings (e.g., angry,
happy, sad, afraid, bad, shy, embarrassed, left out, irrit-
able, fussy, aggressive, anxious, or moody), symptoms
(e.g., headaches, tired) or behavior (e.g., to drink, to eat,
to cook) were not changed.
Discussion
The adaptation of the PKU-QOL questionnaire from
UK English to US English did not reveal major se-
mantic or cultural issues. Participating patients with
PKU and their caregivers provided input essential to
adaptation of the PKU-QOL questionnaire so that
each component could be easily understood by the
US target population. The PKU-QOL questionnaire
was well accepted by the participants of the study,
which supports the assumption that concepts assessed
and identified during the development of the original
PKU-QOL questionnaire [28] were equally relevant to
the US patients and their caregivers. We did not re-
cruit patients based on their phenotype. This was a
deliberate choice since our intent was not to test the
content validity of the US PKU-QOL, but to test how
well the patients understood the questionnaire, and
whether or not the wording was clear and explicit.
However, we acknowledge that, for the future use of
the PKU-QOL, disease phenotype is relevant as the
degree of dietary PHE restriction is impacted by this.
When the PKU-QOL questionnaires are updated in
the future, we intend to include an explanatory sen-
tence acknowledging that some patients may not re-
quire some treatment components (medical food,
special low protein food, etc.), and the questions
should be answered with that in mind.
Other than the initial papers on the development
and use of the PKU-QOL questionnaire in seven
countries [27, 28], published research on cross-
cultural perspectives of quality of life of patients with
PKU is scarce [31]. Most of the cross-cultural evalua-
tions currently published review diagnostic and man-
agement perspectives in various countries [32–35].
The availability of the PKU-QOL questionnaire in
eight countries (i.e., France, Germany, Italy, The
Netherlands, Spain, Turkey, UK and the US) will en-
courage cross-cultural research in PKU, and will be
Table 2 Demographic characteristics of the cognitive interview participants
Participants*
Characteristics Child Adolescent Adult Parent
Age in years:
Range (mean)
9–11 (9.8) 12–17 (14.8) 19–36 (28.4) 31–56 (41)
Gender: males/females 2/3 4/1 2/3 2/3
Level of education 4th–6th grade
(two aged 9 in 4th grade; two
aged 10 in 5th grade; one aged
11 in 6th grade)
6th–11th grade
(one aged 12 in 6th grade; one aged
14 and one aged 15 in 8th grade;
one aged 16 in 9th grade, one aged





*n = 5 for each population
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the first step to wider development and use in various
cultural settings. International studies assessing differ-
ences of impact across cultures would be of great
interest. They would enable cross-cultural compari-
sons and improve awareness, tracking, and manage-
ment of impact on patients with PKU in different
cultures, thus providing opportunity for increased
support. In addition, the cross-cultural equivalence of
the eight language versions of the PKU-QOL ques-
tionnaire (due to the use of rigorous cross-cultural
methodologies [28] during the development phase),
will enable the pooling of data gathered in different
countries, and optimize the chance of demonstrating
treatment benefit. This will be useful in assessing the
impact of standard dietary treatment, pharmacological
treatments such as sapropterin, and potential new
therapies on clinical outcomes.
Conclusions
The adaptation of the UK English PKU-QOL question-
naire into US English did not raise critical semantic and
cultural issues. The four versions of the PKU-QOL ques-
tionnaire are now fully linguistically validated in US
English. The PKU-QOL questionnaire will be valuable
for US healthcare providers in individualizing treatment
and managing patients with PKU. The PKU-QOL ques-
tionnaire will allow patients’ perceptions to be assessed
and documented as patients age, increasing understand-
ing of the impact of PKU on the QOL of patients and
their parents throughout the life cycle. The use of vali-
dated tools to assess the impact of standard dietary ther-
apy, pharmacological treatments such as sapropterin,
and potential new therapies on clinical outcomes will be
valuable in managing patients with PKU in the future,
and will encourage collection of data that is consistent
across treatment centers.
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